AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,946.00p
   
  • Change Today:
      32.00p
  • 52 Week High: 12,294.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.22m
  • Volume: 1,201,194
  • Market Cap: £169,687m
  • RiskGrade: 123

Tuesday broker round-up

By Caoimhe Toman

Date: Tuesday 25 Feb 2020

LONDON (ShareCast) - (Sharecast News) - Redrow: Jefferies upgrades to buy with a target price of 981p.

Admiral Group: Peel Hunt reiterates hold with a target price of 2,230p.

Hiscox: Peel Hunt reiterates reduce with a target price of 1,030p.

Softcat: Peel Hunt initiates buy with a target price of 1,407p.

Ascential: Liberum upgrades to buy with a target price of 420p.

AstraZeneca: Deutsche Bank reiterates buy with a target price of 8,300p.

Clinigen Group: Liberum downgrades to sell with a target price of 820p.

AngloAmerican: Barclays upgrades to overweight with a target price of 2,800p.

B&M European Value Retail: Shore Capital downgrades to hold.

Derwent London: Peel Hunt reiterates hold with a target price of 4,400p.

Dechra Pharmaceuticals: JP Morgan reiterates overweight with a target price of 3,300p.

Boohoo: Citigroup reiterates neural with a target price of 330p.

Smith & Nephew: Berenberg reiterates buy with a target price of 2,335p.

Weir Group: Jefferies reiterates hold with a target price of 1,380p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,946.00p
Change Today 32.00p
% Change 0.29 %
52 Week High 12,294.00
52 Week Low 9,501.00
Volume 1,201,194
Shares Issued 1,550.22m
Market Cap £169,687m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
91.02% below the market average91.02% below the market average91.02% below the market average91.02% below the market average91.02% below the market average
92.45% below the sector average92.45% below the sector average92.45% below the sector average92.45% below the sector average92.45% below the sector average
Price Trend
24.58% above the market average24.58% above the market average24.58% above the market average24.58% above the market average24.58% above the market average
78.95% above the sector average78.95% above the sector average78.95% above the sector average78.95% above the sector average78.95% above the sector average
Income
86.95% below the market average86.95% below the market average86.95% below the market average86.95% below the market average86.95% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average
Growth
81.42% above the market average81.42% above the market average81.42% above the market average81.42% above the market average81.42% above the market average
94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average

What The Brokers Say

Strong Buy 8
Buy 12
Neutral 6
Sell 0
Strong Sell 2
Total 28
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 19-Apr-2024

Time Volume / Share Price
17:46 17,769 @ 10,775.45p
17:08 1,509 @ 10,821.57p
16:37 18 @ 10,946.00p
16:35 550 @ 10,946.00p
16:35 600 @ 10,946.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page